GEN
Gen Digital Inc.
GEN has slightly lower modeled downside risk, despite its lower overall score.
MU
Micron Technology, Inc.
MU has the edge over GEN overall, supported by stronger valuation and stronger modeled upside.
GEN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Stable |
GEN's profitability and cash flow are currently strong, and its revenue and balance sheet are stable.
MU Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
MU's revenue, profitability, cash flow and balance sheet are all currently strong.
GEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.3x | $16.34 | -45% |
| Forward | 9.5x | $29.69 | — |
| Current | 15x | $29.69 | — |
| Fair | 18x | $35.76 | +20% |
| Expensive | 28x | $54.70 | +84% |
Historical ranges are pointers, not guarantees.
GEN's PE is in its cheap range at 15x. If earnings grow as analysts expect, today's price would be 9.5x next year's earnings.
MU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 4.6x | $798 | — |
| Cheap | 10x | $777 | -2.7% |
| Current | 11x | $798 | — |
| Fair | 22x | $1,646 | +106% |
| Expensive | 32x | $2,404 | +201% |
Historical ranges are pointers, not guarantees.
MU has the edge over GEN in the historical PE scenario, which offers more potential upside but is not a forecast.
GEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for GEN, with profitability improving.
MU Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for MU, with profitability improving.
GEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.12 | +58% |
| Q3 2026 | $1.98 | +118% |
| Q2 2026 | $1.71 | +78% |
| Q1 2026 | $1.57 | +52% |
| Q4 2025 | $0.96 | -6.8% |
| Q3 2025 | $0.91 | -8.1% |
| Q2 2025 | $0.96 | 0% |
| Q1 2025 | $1.03 | +7.3% |
| Q4 2024 | $1.03 | -53% |
GEN's earnings per share have fallen from their peak: $1.98 over the past year, against $6.20 in mid-2020.
MU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $174.95 | +135% |
| Q3 2026 | $74.33 | +879% |
| Q2 2026 | $44.17 | +693% |
| Q1 2026 | $21.18 | +405% |
| Q4 2025 | $10.52 | +201% |
| Q3 2025 | $7.59 | +984% |
| Q2 2025 | $5.57 | +$6.99 |
| Q1 2025 | $4.19 | +$7.64 |
| Q4 2024 | $3.49 | +$9.77 |
MU has the edge over GEN on earnings, with more consistent year-over-year improvement.
GEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +12% |
| Q2 2026 | $1.3B | +6.3% |
| Q1 2026 | $1.3B | +27% |
| Q4 2025 | $1.2B | +26% |
| Q3 2025 | $1.2B | +25% |
| Q2 2025 | $1.3B | +30% |
| Q1 2025 | $1B | +4.4% |
| Q4 2024 | $986M | +3.7% |
GEN's revenue has grown year over year every quarter since early 2021: $1.4B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 37% | +1.1 points |
| Q2 2026 | 33% | -2.3 points |
| Q1 2026 | 63% | +21 points |
| Q4 2025 | 35% | -3 points |
| Q3 2025 | 36% | -5.4 points |
| Q2 2025 | 35% | -7.7 points |
| Q1 2025 | 41% | -0.1 points |
| Q4 2024 | 38% | +2.7 points |
GEN's operating margin was 37% last quarter, up 1.1 points from the same quarter a year ago.
MU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.2B | +379% |
| Q2 2026 | $41.5B | +346% |
| Q1 2026 | $23.9B | +196% |
| Q4 2025 | $13.6B | +57% |
| Q3 2025 | $11.3B | +46% |
| Q2 2025 | $9.3B | +37% |
| Q1 2025 | $8.1B | +38% |
| Q4 2024 | $8.7B | +84% |
MU has the edge over GEN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 81% | +48 points |
| Q2 2026 | 80% | +57 points |
| Q1 2026 | 68% | +46 points |
| Q4 2025 | 45% | +20 points |
| Q3 2025 | 32% | +13 points |
| Q2 2025 | 23% | +13 points |
| Q1 2025 | 22% | +19 points |
| Q4 2024 | 25% | +49 points |
MU has the edge over GEN on profitability, with a higher operating margin.
GEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $323M | +202% |
| Q2 2026 | $430M | +6.2% |
| Q1 2026 | $476M | +1.3% |
| Q4 2025 | $535M | +68% |
| Q3 2025 | $107M | -31% |
| Q2 2025 | $405M | +55% |
| Q1 2025 | $470M | -66% |
| Q4 2024 | $318M | +3.6% |
GEN generated $1.8B in free cash flow over the past year, up 36% from the year before.
MU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.9B | +45543% |
| Q2 2026 | $17.6B | +951% |
| Q1 2026 | $5.5B | +$5.6B |
| Q4 2025 | $3B | +7853% |
| Q3 2025 | $72M | -75% |
| Q2 2025 | $1.7B | +322% |
| Q1 2025 | -$113M | +$52M |
| Q4 2024 | $38M | +$433M |
MU has the edge over GEN on cash flow, with more consistent year-over-year improvement.
GEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -3.4% | -21M shares |
| 3 years | -6.4% | -41M shares |
| 5 years | +2% | +12M shares |
| Available history | -6.8% | -44M shares |
GEN has the edge over MU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $171M |
| Q2 2026 | $100M |
| Q1 2026 | $200M |
| Q4 2025 | $300M |
| Q3 2025 | — |
| Q2 2025 | $134M |
| Q1 2025 | — |
| Q4 2024 | — |
GEN spent $771M buying back its own shares over the past year, about six times what it spent the year before.
MU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -2M shares |
| 1 year | +1.6% | +18M shares |
| 3 years | +4.6% | +50M shares |
| 5 years | +0.2% | +2M shares |
| Available history | +1.2% | +14M shares |
MU has 1.1B diluted shares, up 1.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $350M |
| Q4 2025 | $300M |
| Q3 2024 | $300M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
MU has spent almost nothing on buybacks in the past year.
GEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.9x | Moderate |
| Q2 2026 | 3.0x | Moderate |
| Q1 2026 | 3.0x | Elevated |
| Q4 2025 | 3.7x | Elevated |
| Q3 2025 | 3.9x | Elevated |
| Q2 2025 | 4.1x | High |
| Q1 2025 | 3.6x | Elevated |
| Q4 2024 | 3.8x | Elevated |
GEN's net debt is about 2.9 years of its operating earnings (EBITDA), down from 3.9 years a year ago.
MU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
MU has the edge over GEN on leverage, with a lower net debt burden relative to earnings.
GEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.3 | Neutral |
| Stochastic | 81.3 | Overbought |
GEN's weekly RSI is 59 (neutral) and its Stochastic is 81 (overbought).
MU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.1 | Neutral |
| Stochastic | 26.9 | Neutral |
MU's weekly RSI is 47 (neutral) and its Stochastic is 27 (neutral).
GEN PE vs Technology Sector
| Metric | GEN | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 28x | 46% below |
| PE % | 32 | 35 | 3 pts below |
GEN is trading at 15x earnings, a 46% discount to the Technology sector's median of 28x.
MU PE vs Technology Sector
| Metric | MU | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 28x | 61% below |
| PE % | 18 | 35 | 17 pts below |
MU has the edge over GEN on valuation relative to its sector.
GEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.6 | 16% above |
| 20 week MA | $27.2 | 9% above |
| 50 week MA | $25.0 | 19% above |
| 100 week MA | $26.4 | 12% above |
| 200 week MA | $24.2 | 23% above |
GEN has the edge over MU on trend strength, trading above more of its moving averages.
MU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $914.5 | 13% below |
| 20 week MA | $931.0 | 14% below |
| 50 week MA | $685.9 | 16% above |
| 100 week MA | $405.4 | 97% above |
| 200 week MA | $246.0 | 225% above |
MU has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 225% above its 200-week average.
GEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.6 | $21.0 | -18% |
| 2021 | $21.0 | $25.9 | +23% |
| 2022 | $25.9 | $21.3 | -18% |
| 2023 | $21.3 | $22.8 | +7.1% |
| 2024 | $22.8 | $27.7 | +21% |
| 2025 | $27.7 | $27.8 | +0.4% |
| 2026 YTD | $27.8 | $29.7 | +6.9% |
GEN has finished higher in four of the last six years. It's up 6.9% so far in 2026.
MU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.0 | $70.6 | +31% |
| 2021 | $70.6 | $94.4 | +34% |
| 2022 | $94.4 | $50.2 | -47% |
| 2023 | $50.2 | $85.3 | +70% |
| 2024 | $85.3 | $88.6 | +3.9% |
| 2025 | $88.6 | $284.8 | +221% |
| 2026 YTD | $284.8 | $798.4 | +180% |
MU has the edge over GEN on returns for 2026, with the stronger performance.